drugset / Trial / NCT06168214
Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication
RandomizedParallel-groupSingle-blindTreatment
Summary
The goal of this clinical trial is to compare eradication rates of Helicobacter pylori in patients aged 18-70 years with first infection. The main questions it aims to answer are: * Main indicators: the eradication rate of Helicobacter pylori for eradication. * Secondary indicators: symptomatic relief rate at 2 weeks after treatment and 4 weeks after the end of treatment; compliance and adverse reactions during treatment.
Timeline
- Start
- 2023-09-04
- Primary completion
- 2024-11-25
- Completion
- 2024-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 1000 mg | — |
| Comparator | Bismuth Potassium Citrate | Unknown | 240 mg | — |
| Subject | Clarithromycin | Small molecule | 500 mg | — |
| Subject | Furazolidone | Small molecule | 100 mg | — |
| Comparator | Rabeprazole | Small molecule | 10 mg | — |
| Subject | Tetracycline | Unknown | 500 mg | — |
| Subject | Vonoprazan | Other / unclassified | 20 mg | — |
| Comparator | colloidal bismuth pectin | Unknown | 300 mg | — |
| Comparator | colloidal bismuth tartrate | Unknown | 220 mg | — |
Indications
No indication recorded.